mobic and Weight-Gain

mobic has been researched along with Weight-Gain* in 8 studies

Trials

5 trial(s) available for mobic and Weight-Gain

ArticleYear
The effect of different combinations of local anaesthesia, sedative and non-steroidal anti-inflammatory drugs on daily growth rates of dairy calves after disbudding.
    New Zealand veterinary journal, 2016, Volume: 64, Issue:5

    To assess the effect of sedation and local anaesthesia (LA) at disbudding, and the addition of meloxicam or ketoprofen treatment, on weight gain in dairy calves following disbudding.. Friesian-Jersey cross calves, from four dairy farms, were enrolled when 3-6 weeks old. All calves (n=271) were disbudded by veterinary personnel and randomly assigned to six groups: 136 were disbudded without sedation or LA, of which 31 received 20 mg meloxicam S/C and 75 received 150 mg ketoprofen I/M. A further 135 were disbudded with sedation (0.25 mg/kg xylazine I/M) and LA, of which 30 also received meloxicam and 75 received ketoprofen. Calves were weighed 3 days before, and 15 and 30 days after, disbudding (Day 0). Daily weight gain was analysed using mixed models and ANOVA.. Complete results were obtained from 263 calves. From Day -3 to Day 15, the growth rate of calves disbudded without pain relief (0.53 (95% CI=0.47-0.60) kg/day) was less that of calves disbudded with some form of pain relief (0.65 (95% CI=0.62-0.68) kg/d; p=0.004). There was no difference between the effect of meloxicam or ketoprofen (p=1.00). An interaction between use of sedation and LA and additional non-steroidal anti-inflammatory drugs (NSAID) meant that NSAID treatment did not increase growth rates in calves disbudded with sedation and LA but did increase growth rates for calves disbudded without pain relief (p<0.05). From Day 16 to Day 30 there was no effect of NSAID treatment on growth rate, but calves receiving LA and sedation grew faster (0.74 (95% CI=0.69-0.80) kg/day) than calves disbudded without LA and sedation (0.66 (95% CI=0.61-0.71) kg/day; p=0.018). From Day -3 to Day 30, calves disbudded with sedation and LA grew faster (0.71 (95%CI=0.64-0.77) kg/day) than calves disbudded without sedation and LA (0.60 (95% CI=0.55-0.65) kg/day; p=0.011). However, addition of NSAID to sedation and LA made no further difference to growth rates (p=0.69).. Dairy calves disbudded with no pain relief had slower growth rates than calves receiving pain relief. From Day 15 to 30 calves given no pain relief, or NSAID alone, grew more slowly than those receiving sedation and LA at disbudding. The addition of NSAID treatment to sedation and LA did not further increase growth rates.. This study adds to the evidence that pain management when disbudding is beneficial for calf productivity as well as calf welfare.

    Topics: Anesthesia, Local; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cattle; Conscious Sedation; Dairying; Female; Horns; Hypnotics and Sedatives; Ketoprofen; Meloxicam; Thiazines; Thiazoles; Weight Gain; Xylazine

2016
Effect of analgesia and anti-inflammatory treatment on weight gain and milk intake of dairy calves after disbudding.
    New Zealand veterinary journal, 2015, Volume: 63, Issue:3

    To assess the effect of analgesia at disbudding on weight gain and milk intake of dairy calves.. Four disbudding protocols were used on 3- to 6-week-old Friesian-Jersey calves. Farm staff disbudded 101 calves without sedation or local analgesia, of which 51 received 20 mg meloxicam S/C. Veterinary staff disbudded 101 calves with sedation and local analgesia, of which 51 also received 20 mg meloxicam S/C. Calves were weighed before disbudding, 15 and 30 days later, and individual milk consumption was recorded for 11 days. Daily weight gain and milk consumption were analysed using mixed models and ANOVA.. From disbudding (Day 0) to Day 15 farmer-disbudded calves receiving meloxicam grew faster (0.65 kg/day) than calves without meloxicam (0.55 kg/day; p=0.011), but an interaction between operator and meloxicam treatment (p=0.056) meant that meloxicam treatment did not increase growth rates in veterinary-disbudded calves (0.63 vs. 0.64 kg/day; p=0.872). From Days 16-30 there was no significant effect of meloxicam on growth rate, but veterinarian-disbudded calves grew faster (0.76 kg/day) than farmer-disbudded calves (0.66 kg/day; p=0.034). Overall, for the first 30 days after disbudding, if meloxicam was not used', veterinarian-disbudded calves grew faster than farmer-disbudded calves (p=0.002). However if meloxicam was used at disbudding there was no difference in growth rate between veterinarian- and farmer-disbudded calves (p=0.878). Mean cumulative milk consumption for the 11 days after disbudding was greater for calves disbudded by veterinary staff than by farm staff (p<0.001), but there was no effect of meloxicam treatment (p=0.618) and no interaction with operator (p=0.86) on cumulative milk consumption.. Three to 6-week-old dairy calves disbudded by farm staff with no analgesia grew significantly slower over the next 15 days than farmer-disbudded calves given meloxicam, and slower over the next 30 days than veterinarian-disbudded calves given xylazine and lignocaine. However addition of meloxicam to the latter protocol had no effect on growth rate. Milk intake was significantly higher for 11 days for veterinarian- compared with farmer-disbudded calves.. This study adds to the evidence that analgesia during disbudding is beneficial for calf productivity as well as calf welfare.

    Topics: Analgesia; Anesthetics, Local; Animal Husbandry; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cattle; Eating; Horns; Hypnotics and Sedatives; Lidocaine; Meloxicam; Pain; Thiazines; Thiazoles; Weight Gain; Xylazine

2015
Evaluating a novel analgesic strategy for ring castration of ram lambs.
    Veterinary anaesthesia and analgesia, 2012, Volume: 39, Issue:5

    To evaluate the analgesic efficacy of the NSAIDs flunixin and meloxicam administered locally to the scrotum before ring castration.. Randomised, controlled, prospective study.. Forty eight single born male Merino lambs.. Lambs, aged approximately 4 weeks, were allocated to four groups for castration. Groups were: sham control; castration + saline; castration + flunixin; castration + meloxicam. Drugs (5 mL) were administered subcutaneously around the circumference of the scrotum immediately before castration. Cortisol, rectal temperature, haematology and plasma haptoglobin were measured before and up to 48 hours after treatment. Behaviour recorded by video for 12 hours after treatment was classified as pain avoidance behaviours in the first hour and postural behaviours in three 4 hour intervals.. Ring castration (saline group) induced a bi-phasic increase in cortisol with peaks at 90 minutes and 24 hours but no significant changes in haematology, haptoglobin or rectal temperature. Pain avoidance behaviours were increased and teat seeking decreased. Normal lying and normal standing postures were decreased and abnormal ventral lying, statue standing, abnormal standing and total abnormal postures increased. Flunixin decreased cortisol at 90 minutes (60.3 versus 117.3 nmol L(-1) ) and cortisol AUC (0-6 hours), decreased elevated leg movement (2.5 versus 5.4 events) and sum of pain avoidance behaviours (8.5 versus 16.7 events), improved time spent in normal ventral lying and decreased abnormal ventral lying and total abnormal postures compared to saline treated lambs. In a similar contrast, meloxicam caused non-significant decreases in cortisol at 90 minutes, cortisol AUC (0-6 hours) and pain avoidance behaviours, and significantly improved the postural behaviours normal ventral lying (26.7 versus 15.4%) and normal standing (13.9 versus 7.5%), and reduced abnormal standing and total abnormal postures. Physiological and behavioural responses associated with ring castration for both NSAID treatment groups were generally greater than sham controls.. Locally administered NSAIDs provided partial analgesia for ring castration.

    Topics: Analgesics; Animals; Behavior, Animal; Body Temperature; Clonixin; Drug Administration Schedule; Hydrocortisone; Male; Meloxicam; Orchiectomy; Pain; Sheep; Sheep Diseases; Thiazines; Thiazoles; Weight Gain

2012
Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia.
    BMC veterinary research, 2012, Sep-01, Volume: 8

    Dehorning is a common practice involving calves on dairy operations in the United States. However, less than 20% of producers report using analgesics or anesthetics during dehorning. Administration of a systemic analgesic drug at the time of dehorning may be attractive to dairy producers since cornual nerve blocks require 10 - 15 min to take effect and only provide pain relief for a few hours. The primary objectives of this trial were to (1) describe the compartmental pharmacokinetics of meloxicam in calves after IV administration at 0.5 mg/kg and (2) to determine the effect of meloxicam (n = 6) or placebo (n = 6) treatment on serum cortisol response, plasma substance P (SP) concentrations, heart rate (HR), activity and weight gain in calves after scoop dehorning and thermocautery without local anesthesia.. Plasma meloxicam concentrations were detectable for 50 h post-administration and fit a 2-compartment model with a rapid distribution phase (mean T(1/2α) = 0.22 ± 0.087 h) and a slower elimination phase (mean T(1/2β) = 21.86 ± 3.03 h). Dehorning caused a significant increase in serum cortisol concentrations and HR (P < 0.05). HR was significantly lower in the meloxicam-treated calves compared with placebo-treated calves at 8 h (P = 0.039) and 10 h (P = 0.044) after dehorning. Mean plasma SP concentrations were lower in meloxicam treated calves (71.36 ± 20.84 pg/mL) compared with control calves (114.70 ± 20.84 pg/mL) (P = 0.038). Furthermore, the change in plasma SP from baseline was inversely proportional to corresponding plasma meloxicam concentrations (P = 0.008). The effect of dehorning on lying behavior was less significant in meloxicam-treated calves (p = 0.40) compared to the placebo-treated calves (P < 0.01). Calves receiving meloxicam prior to dehorning gained on average 1.05 ± 0.13 kg bodyweight/day over 10 days post-dehorning compared with 0.40 ± 0.25 kg bodyweight/day in the placebo-treated calves (p = 0.042).. To our knowledge, this is the first published report examining the effects of meloxicam without local anesthesia on SP, activity and performance of calves post-dehorning. These findings suggest that administration of meloxicam alone immediately prior to dehorning does not mitigate signs of acute distress but may have long term physiological, behavior and performance effects.

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cattle; Cattle Diseases; Heart Rate; Horns; Hydrocortisone; Meloxicam; Pain; Substance P; Thiazines; Thiazoles; Weight Gain

2012
Optimizing the dosing interval of buprenorphine in a multimodal postoperative analgesic strategy in the rat: minimizing side-effects without affecting weight gain and food intake.
    Laboratory animals, 2012, Volume: 46, Issue:4

    Buprenorphine is commonly used as (part of) postoperative analgesic treatment with dosage dependent side-effects such as pica behaviour. No strict consensus exists about the optimal dosing interval of buprenorphine, as its duration of action has been described as being in the range of 6-12 h. In this study, dosing intervals of 8 h (thrice-a-day) and 12 h (twice-a-day) for buprenorphine in a multimodal analgesic strategy (concurrent administration of a non-steroidal anti-inflammatory drug) were compared on food intake, weight and side-effects (gnawing on plastic Petri dishes and growth rate, indicative of pica behaviour) in rats. The food intake and weight of both intervals were comparable, as the animals from the twice-a-day group did not lose more weight or consumed less food during the analgesic period. The rats from the thrice-a-day group suffered from more side-effects, as the growth rate was decreased and more plastic was gnawed on. It is recommended to carefully evaluate analgesic and side-effects when using buprenorphine. When side-effects are observed, the possibility of increasing the dosing interval of buprenorphine should be explored. In this study, increasing the dosing interval of buprenorphine in a multimodal analgesic regimen resulted in reduced unwanted side-effects, without increasing weight loss or decreasing food intake. Although this is suggestive of provision of comparable analgesia, future studies including more pain-related readout parameters to assess the effect of the dosing interval on analgesic efficacy are recommended.

    Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Buprenorphine; Drug Therapy, Combination; Electrodes, Implanted; Feeding Behavior; Injections, Subcutaneous; Male; Meloxicam; Neurosurgical Procedures; Pain, Postoperative; Pica; Postoperative Care; Rats; Rats, Wistar; Thiazines; Thiazoles; Time Factors; Weight Gain

2012

Other Studies

3 other study(ies) available for mobic and Weight-Gain

ArticleYear
Postpartum meloxicam administration to sows but not split-suckling increases piglet growth and reduces clinical incidence of disease in suckling piglets.
    Journal of animal science, 2023, Jan-03, Volume: 101

    Each suckling pig should receive ≥200 g of colostrum within the first 24 h of life, but with increased litter size this is now difficult to achieve. The aim of this study was to assess the effect of split-suckling and postpartum meloxicam provision to sows as a means of ensuring adequate colostrum intake, on growth and health in pigs pre- and postweaning. One hundred and four sows (Large White × Landrace) and their litters, averaging 16.3 piglets born alive, were assigned to one of four treatments in a two-by-two factorial arrangement. Factors were provision of meloxicam (yes/no; Mel/N-Mel) and split-suckling (yes/no; Split/N-Split). Meloxicam was administered intramuscularly at 0.4 mg/kg body weight to sows on release of the placenta (~2 h postpartum). Split-suckling commenced 4 h after birth of the first piglet, with the six heaviest piglets removed from the sow for 1 h to allow the lightest piglets to suckle. This was repeated after 1.5 h. Pigs were weighed at birth and at days 1, 6, 14, and 27 after birth and at days 6, 14, 21, 28, 47, and 129 postweaning. Carcass data were collected at slaughter. Medication usage was recorded from birth to slaughter. There was a split-suckling by meloxicam interaction effect at days 1 to 6 (P < 0.001) and days 6 to 14 (P < 0.001) after birth. Meloxicam administration had no effect on average daily gain (ADG) when split-suckling was applied; however, when split-suckling was not applied, postpartum meloxicam administration increased ADG. There was a meloxicam × split-suckling interaction for ADG from weaning to day 6 postweaning (P = 0.03). Meloxicam increased ADG when split-suckling was applied but not in its absence. Carcass weight was increased by meloxicam (P = 0.01) but was not affected by split-suckling (P > 0.05). Meloxicam use in sows reduced the number of clinical cases of disease (P = 0.04) in suckling pigs which tended to reduce the volume of antibiotics (P = 0.08) and anti-inflammatories (P = 0.08) administered. Split-suckling had no effect on medication usage in sows and piglets during lactation but increased their use from weaning to slaughter. In conclusion, postpartum administration of meloxicam to sows is an easily implemented strategy. It reduced clinical cases of disease, increased ADG in pigs during the first two weeks of life and early postweaning and increased carcass weight at slaughter. However, no split-suckling benefit was observed.. Suckling pigs should receive ≥200 g of colostrum (the first secretion of the mammary gland after giving birth) within the first 24 h of life. This is challenging to achieve as the number of piglets born alive has increased over the last decade, but the sow’s ability to produce colostrum has not increased. Split-suckling (removing advantaged pigs from the sow for a period of time to allow weaker littermates time to suckle without competition) and/or administering an anti-inflammatory pain-killer to sows after farrowing may help to ensure adequate colostrum intake, thereby ensuring optimal piglet growth and health. The objective of this study was to assess the effect of split-suckling and/or postpartum provision of meloxicam, a nonsteroidal anti-inflammatory, on growth and health in pigs. The provision of meloxicam to sows increased pig growth pre- and postweaning, and increased carcass weight at slaughter. Furthermore, meloxicam reduced disease and tended to reduce antibiotic and anti-inflammatory usage in pigs prior to weaning. Split-suckling reduced pig growth pre- and postweaning and did not impact carcass weight or medication usage prior to weaning. Providing meloxicam to sows postfarrowing is a simple effective strategy to increase pig growth and reduce the need for medication.

    Topics: Animals; Female; Incidence; Lactation; Meloxicam; Parturition; Postpartum Period; Pregnancy; Swine; Weight Gain

2023
Correlation between body weight changes and postoperative pain in rats treated with meloxicam or buprenorphine.
    Lab animal, 2009, Volume: 38, Issue:3

    It is essential to identify objective and efficient methods of evaluating postoperative pain in rodents. The authors investigated whether postoperative changes in rates of body weight gain could serve as a measure of the efficacy of meloxicam or buprenorphine analgesia in growing rats. Young adult male Lewis rats underwent general endotracheal anesthesia and thoracotomy and were treated postoperatively for 3 d with saline (no analgesia), buprenorphine (six doses of 0.1 mg per kg) or meloxicam (three doses of 1 mg per kg). The authors evaluated rats' daily growth rates for 5 d after surgery and compared them with baseline (preoperative) growth rates. To discriminate between the effects of postoperative pain and other concurrent physiologic effects associated with anesthesia, thoracotomy or analgesia, the authors evaluated weight changes in multiple control groups. Treatment with buprenorphine in the absence of any other procedure or with anesthesia alone significantly affected rats' body weight. Notably, growth rate was maintained at near normal levels in rats treated postoperatively with meloxicam. These findings suggest that growth rate might serve as an efficient index of postoperative pain after major surgical procedures in young adult rats treated with meloxicam but not in rats treated with buprenorphine.

    Topics: Analgesia; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Buprenorphine; Intubation, Intratracheal; Meloxicam; Pain, Postoperative; Rats; Rats, Inbred Lew; Thiazines; Thiazoles; Thoracotomy; Weight Gain

2009
Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation.
    American journal of physiology. Endocrinology and metabolism, 2007, Volume: 292, Issue:6

    Chronic arthritis induces cachexia associated with an inhibition of the growth hormone (GH)-insulin-like growth factor-I (IGF-I) system and an activation of the E3 ubiquitin-ligating enzymes muscle atrophy F-box (MAFbx) and muscle Ring finger 1 (MuRF1) in the skeletal muscle. The aim of this work was to study the role of cyclooxygenase (COX)-2 in chronic arthritis-induced cachexia. Arthritis was induced in rats by Freund's adjuvant injection, and the effects of two COX inhibitors (indomethacin, a nonspecific inhibitor, and meloxicam, a selective COX-2 inhibitor on pituitary GH and on liver and serum IGF-I levels) were tested. Arthritis decreased body weight gain and GH and liver IGF-I gene expression. In the arthritic rats, both inhibitors, indomethacin and meloxicam, prevented the inhibitory effect of arthritis on body weight gain. Indomethacin and meloxicam administration to arthritic rats increased pituitary GH and liver IGF-I mRNA as well as serum levels of IGF-I. These data suggest that induction of COX-2 during chronic inflammation is involved in the inhibition of the GH-IGF-I axis and in the body weight loss. In the gastrocnemius muscle, arthritis increased the gene expression of tumor necrosis factor (TNF)-alpha, the E3 ubiquitin-ligating enzymes MAFbx and MuRF1, as well as of IGF-I and IGF-binding protein-5 (IGFBP-5). Inhibition of COX-2 by meloxicam administration increased gastrocnemius weight and decreased MAFbx, MuRF1, TNF-alpha, and IGFBP-5 gene expression. In summary, our data indicate that chronic arthritis-induced cachexia and muscle wasting are mediated by the COX-2 pathway resulting in a decreased GH-IGF-I secretion and increased expression of MAFbx and MuRF1 mRNA.

    Topics: Animals; Arthritis, Experimental; Cachexia; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Activation; Gene Expression; Growth Hormone; Indomethacin; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Liver; Male; Meloxicam; Muscle Proteins; Muscle, Skeletal; Pituitary Gland; Rats; Rats, Wistar; RNA, Messenger; SKP Cullin F-Box Protein Ligases; Thiazines; Thiazoles; Tripartite Motif Proteins; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Weight Gain

2007